1-20 of 29
Michael Andreeff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia

Xuejie Jiang, Po Yee Mak, Hong Mu, Wenjing Tao, Duncan H. Mak, Steven Kornblau, Qi Zhang, Peter Ruvolo, Jared K. Burks, Weiguo Zhang, Teresa McQueen, Rongqing Pan, Hongsheng Zhou, Marina Konopleva, Jorge Cortes, Qifa Liu, Michael Andreeff, Bing Z. Carter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2417–2429.
https://doi.org/10.1158/1078-0432.CCR-17-1556
Published: 14 May 2018
View article titled, Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <em>FLT3</em>-Mutant Acute Myeloid Leukemia
Open the PDF for Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <em>FLT3</em>-Mutant Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3

Weiguo Zhang, Hongying Zhang, Andrea Local, William G. Rice, Charlie J. Ly, Guopan Yu, Stephen B. Howell, Michael Andreeff
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 25.
https://doi.org/10.1158/1557-3265.HEMMAL17-25
Published: 14 December 2017
View article titled, Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3
Journal Articles

Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

Koichi Takahashi, Feng Wang, Kiyomi Morita, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zahr, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiu Wu, Steven Kornblau, Courtney DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop Kantarjian, Jorge Cortes, Marina Konopleva, Andrew Futreal
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 16.
https://doi.org/10.1158/1557-3265.HEMMAL17-16
Published: 14 December 2017
View article titled, Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)
Journal Articles

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression

Heather J. Dalton, Sunila Pradeep, Michael McGuire, Yared Hailemichael, Shaolin MA, Yasmin Lyons, Guillermo N. Armaiz-Pena, Rebecca A. Previs, Jean Marie Hansen, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Min Soon Cho, Sherry Y. Wu, Lingegowda S. Mangala, Nicholas B. Jennings, Wei Hu, Robert Langley, Hong Mu, Michael Andreeff, Menashe Bar-Eli, Willem Overwijk, Prahlad Ram, Gabriel Lopez-Berestein, Robert L. Coleman, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7034–7046.
https://doi.org/10.1158/1078-0432.CCR-17-0647
Published: 14 November 2017
View article titled, Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Open the PDF for Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression in another window
Includes: Supplementary data
Journal Articles

Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress

Fuling Zhou, Yunbao Pan, Yongchang Wei, Ronghua Zhang, Gaigai Bai, Qiuju Shen, Shan Meng, Xiao-Feng Le, Michael Andreeff, Francois X. Claret
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4450–4461.
https://doi.org/10.1158/1078-0432.CCR-16-2426
Published: 01 August 2017
View article titled, Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress
Open the PDF for Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress in another window
Includes: Supplementary data
Journal Articles

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath AI-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3385–3395.
https://doi.org/10.1158/1078-0432.CCR-16-1904
Published: 02 July 2017
View article titled, Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Open the PDF for Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Juliana Benito, Marc S. Ramirez, Niki Zacharias Millward, Juliana Velez, Karine G. Harutyunyan, Hongbo Lu, Yue-xi Shi, Polina Matre, Rodrigo Jacamo, Helen Ma, Sergej Konoplev, Teresa McQueen, Andrei Volgin, Marina Protopopova, Hong Mu, Jaehyuk Lee, Pratip K. Bhattacharya, Joseph R. Marszalek, R. Eric Davis, James A. Bankson, Jorge E. Cortes, Charles P. Hart, Michael Andreeff, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1687–1698.
https://doi.org/10.1158/1078-0432.CCR-14-3378
Published: 31 March 2016
View article titled, Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Open the PDF for Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models in another window
Includes: Supplementary data
Journal Articles

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 868–876.
https://doi.org/10.1158/1078-0432.CCR-15-0481
Published: 14 February 2016
View article titled, Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Open the PDF for Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia in another window
Includes: Supplementary data
Journal Articles

Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

Weiguo Zhang, Chen Gao, Marina Konopleva, Ye Chen, Rodrigo O. Jacamo, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2363–2374.
https://doi.org/10.1158/1078-0432.CCR-13-2052
Published: 30 April 2014
View article titled, Reversal of Acquired Drug Resistance in <em>FLT3</em>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Open the PDF for Reversal of Acquired Drug Resistance in <em>FLT3</em>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies in another window
Includes: Supplementary data
Journal Articles

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Marina Y. Konopleva, Roland B. Walter, Stefan H. Faderl, Elias J. Jabbour, Zhihong Zeng, Gautam Borthakur, Xuelin Huang, Tapan M. Kadia, Peter P. Ruvolo, Jennie B. Feliu, Hongbo Lu, LaKiesha Debose, Jan A. Burger, Michael Andreeff, Wenbin Liu, Keith A. Baggerly, Steven M. Kornblau, L. Austin Doyle, Elihu H. Estey, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-13-1978
Published: 15 April 2014
View article titled, Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Open the PDF for Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J. Meyer, Deborah A. Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3396–3406.
https://doi.org/10.1158/1078-0432.CCR-11-2703
Published: 14 June 2012
View article titled, A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors

Ann H. Klopp, Yan Zhang, Travis Solley, Felipe Amaya-Manzanares, Frank Marini, Michael Andreeff, Bisrat Debeb, Wendy Woodward, Rosemarie Schmandt, Russell Broaddus, Karen Lu, Mikhail G. Kolonin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3): 771–782.
https://doi.org/10.1158/1078-0432.CCR-11-1916
Published: 31 January 2012
View article titled, Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors
Open the PDF for Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors in another window
Includes: Supplementary data
Journal Articles

Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance

Jing Lu, Ming Tan, Wen-Chien Huang, Ping Li, Hua Guo, Ling-Ming Tseng, Xiao-hua Su, Wen-Tao Yang, Warapen Treekitkarnmongkol, Michael Andreeff, Fraser Symmans, Dihua Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1326–1334.
https://doi.org/10.1158/1078-0432.CCR-08-0954
Published: 19 February 2009
View article titled, Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance
Open the PDF for Mitotic Deregulation by Survivin in ErbB2-Overexpressing Breast Cancer Cells Contributes to Taxol Resistance in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies

Maryla Krajewska, Shinichi Kitada, Jane N. Winter, Daina Variakojis, Alan Lichtenstein, Dayong Zhai, Michael Cuddy, Xianshu Huang, Frederic Luciano, Cheryl H. Baker, Hoguen Kim, Eunah Shin, Susan Kennedy, Allen H. Olson, Andrzej Badzio, Jacek Jassem, Ivo Meinhold-Heerlein, Michael J. Duffy, Aaron D. Schimmer, Ming Tsao, Ewan Brown, Anne Sawyers, Michael Andreeff, Dan Mercola, Stan Krajewski, John C. Reed
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3011–3021.
https://doi.org/10.1158/1078-0432.CCR-07-1955
Published: 15 May 2008
View article titled, Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies
Open the PDF for Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies in another window
Journal Articles

Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma

Elias Drakos, Athanasios Thomaides, L. Jeffrey Medeiros, Jiang Li, Vasiliki Leventaki, Marina Konopleva, Michael Andreeff, George Z. Rassidakis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3380–3387.
https://doi.org/10.1158/1078-0432.CCR-06-2581
Published: 01 June 2007
View article titled, Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
Open the PDF for Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells

Shishir Shishodia, Gautam Sethi, Marina Konopleva, Michael Andreeff, Bharat B. Aggarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1828–1838.
https://doi.org/10.1158/1078-0432.CCR-05-2044
Published: 21 March 2006
View article titled, A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells
Open the PDF for A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells in another window
Journal Articles

Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia

Ettore Biagi, Raphael Rousseau, Eric Yvon, Mary Schwartz, Gianpietro Dotti, Aaron Foster, Diana Havlik-Cooper, Bambi Grilley, Adrian Gee, Kelty Baker, George Carrum, Lawrence Rice, Michael Andreeff, Uday Popat, Malcolm Brenner
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 6916–6923.
https://doi.org/10.1158/1078-0432.CCR-05-0484
Published: 03 October 2005
View article titled, Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia
Open the PDF for Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window